---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-005208"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2026-02-05T23:59:59+00:00"
generated_at: "2026-05-16T04:45:34.377875+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Positive interim Phase 2 data for Ampligen+Imfinzi in metastatic pancreatic cancer

## Summary
- 18 patients enrolled in DURIPANC Phase 2; combination well-tolerated with only two grade 3 immune-related AEs.
- Promising PFS and OS from Phase 1 continue in Phase 2; detailed data expected for publication later this year.
- Patients report high quality of life during treatment despite advanced PDAC.
- Immune profiling shows coordinated activation of innate and adaptive immune responses by Ampligen+durvalumab.
- AIM holds US patent for Ampligen+anti-PD-L1 combination to 2039; orphan drug designations in US and EU.

## SEC filing metadata
- accession: 0001493152-26-005208
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2026-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315226005208/0001493152-26-005208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315226005208/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-005208
- JSON: https://secwatch.observer/filing/0001493152-26-005208.json
- Plain text: https://secwatch.observer/filing/0001493152-26-005208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.